Velkeniers B, Dogusan Z, Naessens F, Hooghe R, Hooghe-Peters E L
Department of Pharmacology, Medical School, Free University of Brussels (VUB), Belgium.
Cell Mol Life Sci. 1998 Oct;54(10):1102-8. doi: 10.1007/s000180050239.
Prolactin (PRL) and growth hormone (GH) qualify as lymphoid growth and differentiation factors. Yet, long-standing hyper- or hyposecretion of PRL or GH does not induce any significant alteration of the immune system. Subclinical changes in laboratory parameters (such as chemotaxis or phagocytosis by granulocytes or macrophages or natural killer cell activity) have been reported in some of these conditions. The GH-insulin-like growth factor (IGF)-I axis is dysregulated in ageing, in catabolic states and in critical illness. Immune parameters, such as infection rate, are being monitored during clinical trials with GH or IGF-I. Hyperprolactinaemia may play an aggravating role in systemic lupus erythematosus, in autoimmune thyroiditis and in other autoimmune diseases. The patient may benefit from increased alertness about interactions between the endocrine and immune systems.
催乳素(PRL)和生长激素(GH)可被视为淋巴细胞生长和分化因子。然而,长期的高催乳素血症或低催乳素血症,以及长期的生长激素分泌过多或过少,均不会引起免疫系统的任何显著改变。在其中一些情况下,已报告实验室参数出现亚临床变化(如粒细胞、巨噬细胞的趋化性或吞噬作用,或自然杀伤细胞活性)。生长激素 - 胰岛素样生长因子(IGF)-I轴在衰老、分解代谢状态和危重病中失调。在使用生长激素或胰岛素样生长因子 -I进行临床试验期间,正在监测免疫参数,如感染率。高催乳素血症可能在系统性红斑狼疮、自身免疫性甲状腺炎和其他自身免疫性疾病中起加重作用。患者可能会从提高对内分泌系统与免疫系统之间相互作用的警惕性中受益。